+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
ID06827613

Phase 1b2 Open-Label Study of Invikafusp Alfa STAR0602 with Sacituzumab Govitecan for Advanced or Metastatic Solid Tumors

Led by Marengo Therapeutics, Inc. · Updated on 2025-09-24

50

Participants Needed

8

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of a new combination treatment for people with advanced solid tumors that cannot be removed by surgery. The study focuses on Invikafusp alfa STAR0602, a special antibody that targets T cell receptors, combined with another drug called Sacituzumab Govitecan. This Phase 1b2 open-label trial aims to better understand how this combination works in patients with serious breast cancers, including triple negative and hormone receptor-positive types. Participants in this study will receive STAR0602 and Sacituzumab Govitecan through intravenous infusions. The trial includes two parts an initial safety phase to find the best dose and a later phase to expand the group of participants at that dose. Treatments are given in cycles lasting 21 days, and patients will be closely monitored throughout the study to assess treatment responses and side effects. During the trial, participants will undergo evaluations such as imaging scans CT or MRI to measure tumor size and blood tests to monitor drug levels and safety. Researchers will track tumor responses, disease control, survival times, and any side effects for up to three years. The study includes regular visits for assessments and safety monitoring, ensuring careful follow-up over the course of participation.

CONDITIONS

Brief Title

A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors

Research Team

K

Kevin Chin, MD, MS

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here